Milind Javle
@JavleMilind
Hubert L and Olive Stringer Professor GI Medical Oncology and Attending Physician, MD Anderson Cancer Center
Chair, NCI Task Force Hepatobiliary Cancers
ID:1357532036475596800
05-02-2021 03:30:48
683 Tweets
1,3K Followers
325 Following
Follow People
One of the greatest medical breakthroughs in 2023: Malaria vaccine will soon be available! Generated by Oxford University and Serum Institute of India Gavi, the Vaccine Alliance and@Gates foundation. A disease that still claims>600K lives annually. who.int/news/item/21-1…
So excited to do this with two of my faves at #GI24 ! Tanios Bekaii-Saab, MD Milind Javle Cholangiocarcinoma Foundation PeerView University of Arizona Cancer Center
Relieved to pass ABIM recertification. However, after working in a focused GI cancer field >17 years..was it of any value to get examined in leukemia, NSCLC, breast cancer, GYN, and so on (also $$cost) Is this the best recertification model for subspecialists American Board of Internal Medicine (ABIM)?
Congrats to everyone who passed their #Oncology boards. Sharing my cheat sheet* i made right before the exam. Thanks to TwoOncDocs and Hemeoncquestions #MedTwitter
*these are my personal notes; can’t attest to accuracy use at your own risk
icloud.com/notes/097Kt1lq…
Tinengotinib VS. Physician's Choice for Patients With FGFR-altered Cholangiocarcinoma (FIRST-308) classic.clinicaltrials.gov/ct2/show/NCT05… First phase 3 trial: FGFR-inhibitor refractory CCA open! Cholangiocarcinoma Foundation Craine’s Cholangiocarcinoma Crew Melinda Bachini MD Anderson Cancer Center AMMF ENS-CCA #TransThera #livertwitter
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma - Journal of Hepatology. Wonderful work by Tim DiPieri and Funda Meric Cholangiocarcinoma Foundation MD Anderson Cancer Center ENS-CCA journal-of-hepatology.eu/article/S0168-…
Convergent MAPK pathway alterations mediate acquired resistance to FGFRi in FGFR2 fusion-positive CCC
Journal of Hepatology
doi.org/10.1016/j.jhep…
👍Additional clinical evidence
👇see also our preclinical work in HEPATOLOGY Journal
doi.org/10.1016/j.jhep…
EASLnews ILCA ESMO - Eur. Oncology…
Overwhelmed 😰 with so many #FGFR inhibitors being developed in #CCA ?
Our #review was just published in #CancerTreatmentReviews by Elsevier 😊
Have a look 👀📖- link 👇
sciencedirect.com/science/articl…
Victor Moreno Mairead G McNamara Fundación Jiménez Díaz The Christie NHS The University of Manchester
Thanks all for a wonderful experience @ 6th APCC at Tata Memorial Hospital, Mumbai. Wonderful engagement and learning. Cholangiocarcinoma Foundation MD Anderson Cancer Center Prajnan Das, MD, MS, MPH Dr. Shubham Pant Amol Patel Shailesh V. Shrikhande bhawna sirohi
FDA approves pembrolizumab with chemotherapy for biliary tract cancer fda.gov/drugs/resource…
👉good news, more options for our patients...
🧐Let's see how long it will take to get it approved by EMA...
ESMO - Eur. Oncology EASLnews ILCA #livertwitter
bhawna sirohi Milind Javle kicking off the Asia Pacific Cholangiocarcinoma Foundation at Tata Memorial Centre in #Mumbai . Looking forward to an amazing meeting and collaboration Cholangiocarcinoma Foundation MD Anderson Cancer Center
Results from a Phase II trial led by our Dr. Milind Javle (abstract 95MO) show FGFR inhibitor tinengotinib may allow patients with bile duct cancer to live longer without disease progression.
Learn more: brnw.ch/21wDKC6 Milind Javle #ESMO23 ESMO - Eur. Oncology #EndCancer
That’s a wrap for #CCASummit2023 Delighted to catch up with friends and colleagues from our #cholangiocarcinoma family 💚
See you next October in Lost Pines, TX
Thank you Milind Javle Flavio G Rocha, MD, FACS, FSSO for invitation to participate at #CCA2023 ! Highly enjoyable and informative session with Dr. Jennifer Knox at the helm!
Kicking off the 5th Anniversary #Cholangiocarcinoma Summit in Scottsdale, AZ 🌵 #CCA2023 Amplity Medical Communications
Join us for the Cleveland Clinic Cholangiocarcinoma Symposium on November 10, at Taussig Cancer Center. Learn from Cleveland Clinic experts along with special guest Dr. Milind Javle from MDAnderson.
Craine’s Cholangiocarcinoma Crew Milind Javle Cleveland Clinic
Register at cholangiocarcinoma.org/cleveland-2023/
Welcome to 6 Asia Pacific Cholangiocarcinoma Conference Mumbai Nov 1/2, 2023. Providers, scientists, patients, caregivers, advocates welcome Tata Memorial Hosp, Registration free: riverroute.in/apccf2023
Cholangiocarcinoma Foundation ENS-CCA AMMF MD Anderson Cancer Center Tata Memorial Centre IndianCancerSociety
📣Join us for the 2023 Cleveland Regional Symposium on Nov 10 , 2023 at Taussig Cancer Center. Learn about cholangiocarcinoma from Cleveland Clinic experts.
Special guest: Dr. Milind Javle from MD Anderson Cancer Center. Register for this educational event at cholangiocarcinoma.org/cleveland-2023/.